December 16, 2004 Big deals pushed biotech higher while the broad market declined. The Centient Biotech 200 moved up by 18.6 points to 3515, a move of .53%. Meanwhile, the NYSE Composite dropped .4% and Nasdaq lost a bunch, about .76%. Johnson & Johnson moved higher on its takeover of Guidant, while CancerVax got $37 million from a partner, Amgen and Sepracor both received an FDA approval, and AVANIR filed for one.
